国产美罗培南治疗急性细菌性感染的临床试验  

Clinical trial of domestic meropenem in treatment of acute bacterial infections

作　　者：金阳[1] 李元桂[1] 傅玲[2] 张建初[1] 辛建保[1] 白明[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院呼吸内科,武汉430022 [2]华中科技大学同济医学院附属协和医院肾病内科,武汉430022

出　　处：《中国新药杂志》2004年第12期1151-1153,共3页Chinese Journal of New Drugs

摘　　要：目的:研究国产美罗培南用于抗感染治疗的临床疗效和安全性。方法:将30例中、重度急性细菌性感染患者按随机对照平行法分成2组,治疗组14例,给予美罗培南0.5g,q8h,静脉滴注;对照组16例,给予泰能(亚胺培南/西司他丁)1.0g,q8h,静脉滴注。两药疗程均为7～10d。结果:两组的临床痊愈率均为50%;临床有效率治疗组和对照组分别为85.7%和87.5%;细菌清除率分别为84.6%和85.7%;不良反应发生率分别为14.3%和18.8%。以上指标两组差异均无显著性(P>0.05)。结论:国产新药美罗培南用于抗感染治疗安全有效。Objective:To study the efficacy and safety of meropenem in treatment of acute bac-terial infections.Methods:30 patients with moderate or serious acute bacterial infections were randomlydivided to receive meropenem infusion in a dose of 0.5g 3 times daily (n=14) for 7～10d or infusiontienam in a dose of 1.0g 3 time daily (n=16) for 7～10d.Results:The curative rate for bothmeropenem and tienam groups was 50%;the effective rate was 85.7% for meropenem group and87.5% for tienam group,bacterial clearance rate was 84.6% for meropenem group and 85.7% fortienam group.The incidence of adverse reaction was 14.3% for meripenem group and 18.8% for tien-am group.Conclusion:Results indicated that the efficacy and safety of domestic meropenam is similarto that of tienam.

关 键 词：美罗培南 亚胺培南佰司他丁 细菌感染 

分 类 号：R978.11[医药卫生—药品] R969.4[医药卫生—药学]